尤瑞克林治疗急性脑梗死对患者血清1型纤溶酶原激活物抑制剂水平及血小板参数的影响  

Effect of urinary kallidinogenase on serum type 1 plasminogen activator inhibitor level and platelet parameters in patients with acute cerebral infarction

作　　者：甘露[1] 甘本辉 江剑辉[1] GAN Lu;GAN Benhui;JIANG Jianhui(Department of Neurological,Fengcheng People's Hospital,Yichun,Jiangxi,331100,China)

机构地区：[1]丰城市人民医院神经内科,江西宜春331100

出　　处：《当代医学》2024年第7期6-10,共5页Contemporary Medicine

摘　　要：目的探究尤瑞克林治疗急性脑梗死对患者血清1型纤溶酶原激活物抑制剂(PAI-1)水平及血小板参数的影响。方法回顾性分析2020年1月至2022年5月丰城市人民医院收治的82例急性脑梗死患者的临床资料,根据使用药物不同分为观察组(n=47)与对照组(n=35)。对照组采用阿司匹林联合氯吡格雷治疗,观察组在对照组基础上联合尤瑞克林治疗。比较两组临床疗效、美国国立卫生研究院卒中量表(NIHSS)、血清PAI-1、血小板计数(PLT)、血小板体积分布宽度(PDW)、血小板平均体积(MPV)、血小板压积(PCT)、血小板黏附率(PAdT)、血小板聚集率(PAgT)、全血黏度、血浆黏度、不良反应发生率。结果观察组治疗总有效率为89.36%,高于对照组的71.43%,差异有统计学意义(P<0.05)。治疗前、治疗7 d,两组NIHSS评分比较差异无统计学意义;治疗14 d,观察组NIHSS评分低于对照组,差异有统计学意义(P<0.05)。治疗14 d,两组血清PAI-1水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗14 d,两组PLT均高于治疗前,PDW均窄于治疗前,MPV、PCT均小于治疗前,PAdT、PagT均低于治疗前,且观察组PLT高于对照组,PDW窄于对照组,MPV、PCT均小于对照组,PAdT、PagT均低于对照组,差异有统计学意义(P<0.05)。治疗14 d,两组全血黏度、血浆黏度均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论尤瑞克林治疗急性脑梗死效果显著,可降低患者血清PAI-1水平及全血黏度、血浆黏度,改善血小板参数,值得临床推广应用。Objective To investigate the effect of urinary kallidinogenase on serum type 1 plasminogen activator inhibitor(PAI-1)level and platelet parameters in patients with acute cerebral infarction.Methods The clinical data of 82 patients with acute cerebral infarction admitted to Fengcheng People's Hospital from January 2020 to May 2022 were retrospectively analyzed,and they were divided into the observation group(n=47)and the control group(n=35)according to the different drugs used.The control group was treated with aspirin combined with clopidogrel,and the observation group was treated with urinary kallidinogenase on the basis of the control group.The clinical efficacy,National Institutes of health stroke scale(NIHSS),serum PAI-1,platelet count(PLT),platelet volume distribution width(PDW),mean platelet volume(MPV),plateletcrit(PCT),plate-let adhesion rate(PAdT),platelet aggregation rate(PAgT),whole blood viscosity,plasma viscosity and adverse reaction rate were compared between the two groups.Results The total effective rate of treatment in the observation group was 89.36%,which was higher than 71.43%in the control group,and the difference was statistically significant(P<0.05).Before treatment and 7 d after treatment,there was no significant difference in NI-HSS score between the two groups;after 14 d of treatment,the NIHSS score in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).After 14 d of treatment,the levels of serum PAI-1 of the two groups were lower than before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).After 14 d of treatment,PLT of the two groups was higher than that before treatment,PDW was narrower than that before treatment,MPV and PCT were smaller than those before treatment,PAdT and PagT were lower than those before treatment,and PLT in the observation group was higher than that in the control group,PDW was narrower than that in the control group,MPV and

关 键 词：血清1型纤溶酶原激活物抑制剂 血小板 急性脑梗死 尤瑞克林 

分 类 号：R743.33[医药卫生—神经病学与精神病学]